Recent News

• 07.29.2026 - Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results
• 07.09.2026 - Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026
• 06.17.2026 - Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
• 06.15.2026 - Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
• 06.15.2026 - Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
• 05.29.2026 - At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
• 05.21.2026 - Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
• 05.05.2026 - Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
• 04.15.2026 - Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
• 02.05.2026 - Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Recent Filings

• 07.30.2026 - 144 Report of proposed sale of securities
• 07.29.2026 - 8-K Current report
• 07.29.2026 - EX-99.1 EX-99.1
• 07.23.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.21.2026 - 144 Report of proposed sale of securities
• 07.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.16.2026 - 144 Report of proposed sale of securities
• 07.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities